Amanote Research
Register
Sign In
Assessment of Pulmonary Arterial Hypertension (PAH) Risk in Sickle Cell Disease Patients Using Plasma Apolipoproteins
Science-Business eXchange
doi 10.1038/scibx.2008.1119
Full Text
Open PDF
Abstract
Available in
full text
Date
December 1, 2008
Authors
Unknown
Publisher
Springer Science and Business Media LLC
Related search
Pulmonary Hypertension in Sickle Cell Disease
New England Journal of Medicine
Medicine
P2 In-Flight Hypoxaemia in Patients With Pulmonary Arterial Hypertension (PAH)
Thorax
Pulmonary
Respiratory Medicine
Sildenafil Therapy in Patients With Sickle Cell Disease and Pulmonary Hypertension
British Journal of Haematology
Hematology
Risk Assessment in Patients With Systemic Sclerosis and Pulmonary Arterial Hypertension
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Relative Systemic Hypertension in Patients With Sickle Cell Disease Is Associated With Risk of Pulmonary Hypertension and Renal Insufficiency
American Journal of Hematology
Hematology
Preoperative Risk Assessment of Pulmonary Arterial Hypertension Patients Undergoing General Surgery
Advances in Pulmonary Hypertension
Clinical Profiling of Sickle Cell Disease Patients With Respect to Pulmonary Hypertension
International Journal of Scientific Reports
Endothelin Receptor Antagonists for Pulmonary Hypertension in Adult Patients With Sickle Cell Disease
British Journal of Haematology
Hematology
Effects of Inhaled Aviptadil (Vasoactive Intestinal Peptide) in Patients With Pulmonary Arterial Hypertension (PAH)
